Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
A Phase 3 randomized clinical trial of oral GnRH antagonist pre-treatment for women with
endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The
investigators' central hypothesis is that in infertile woman with endometriosis undergoing in
vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those
pretreated with GnRH antagonist compared to placebo.
Phase:
Phase 3
Details
Lead Sponsor:
Yale University
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Northwestern University University of Colorado, Denver University of North Carolina